OUR MISSION
STOP & PREVENT
| MACROPHAGE-SUPERCHARGED CANCERS
| EXCESS DEATHS, AND
| OTHER POST-COVID IMMUNE DISORDERS
OUR VIEW & FOCUS
PANDEMIC BROKE OUR IMMUNITY
It is now undeniable - COVID19 broke our immunity with grim consequences.
In the endemic era of 2023, we are witnessing 20% or higher excess deaths in teenagers and working adults under the age of 45, mainly from the unexpected rise in heart attacks and strokes in the young people (read).
Renal, hematological, colon, and lung cancer risks in younger people were found escalated within 3 months of COVID19 infection, with the highest 115% risk increase seen in women (read).
Untreated and often untreatable immune disorders, now dubbed as Long COVID, is keeping millions of people from infants to elderlies in sickness (read).
We decided to do something about it.
OUR APPROACH TO THE PROBLEMS
The immunity problem of dysfunctional macrophages has been the focus of Xylonix from its inception that led to the development of our oncology agent C010DS-Zn (read), as it is the driving feature of immune-evasive, highly metastatic, and treatment resistant cancers (read). Given this background, we quickly identified the long-term health effects of COVID19 such as myocarditis, diabetes, and MIS-C since the early days of the pandemic (read) based on the close resemblance between the COVID-reprogrammed macrophages (read) and the tumor-associated macrophages (read). Since then, we prepared for the scientific frameworks for its prevention and treatment as the following (read, read).
Reduce the infection frequency of COVID19 and other viral infectious diseases. Risks of deaths and hospitalizations from all cause exponentially increase after repeat infections from COVID19 (read). We developed nasal PVD-Iodine-based antiseptics products suitable for frequent disinfection to help curb the re-infection risks from broad pathogens and promote nasal hygiene. Available now.
Reduce baseline systemic inflammation. Chronic systemic exposure to inflammatory antigens contribute to systemic inflammation and aggravation toward autoimmune disease pathologies through dysbiosis. We developed a product for efficient removal of fecal endotoxin sources, which is a major source of inflammatory antigens in many autoimmune diseases (read). Now available, worldwide.
Normalize the broken macrophage immunity to fight the supercharged cancer and long COVID. With COVID19 becoming an endemic disease, the immune dysfunctions that drive the turbocharged cancers and long COVIDs can happen to anyone after repeat infections. While the virus cannot be stopped, we are working with collaborators at Duke-NUS to stop the cancers and long COVIDs by normalizing the broken macrophage immunity (read).
Oncology | Treatments & Diagnostics
Post-pandemic macrophage-enriched cancer treatments. Immune initiation. Metastasis, relapse control. Prognosis.
Detox | Exosomes | Systemic inflammation
Endotoxin/exotoxin removal for digestive disorders, aging, oncology, and systemic de-inflammation.
Nasal Protection | Anti-Dysbiosis
Infectious disease control. Allergy. Rhinitis. Sinusitis. Chronic congestions. Nasal hygiene implementation.
BLOG
OUR MISSION IN ACTION
We ACT on our mission to help people stay safer & healthier through publications, free seminars, and donations to our community.
Visit our Instagram for upcoming events and latest updates.
KEY PUBLICATIONS AND PRESENTATIONS
Click here for our full publication list.
PRESENTATIONS
| Chung, J. F. COVID19 briefs for DB Schenker: Importance of prevention and hygiene practices. DB Schenker COVID19 Response Conference (24 Apr 2020)
This was an invited lecture for COVID19 response call hosted by DB Schenker Singapore and its customers at the start of the global COVID19 pandemic on 24 Apr 2020, covering the topics of threat assessment, future course forecast, plausibility assessment on the discussed response measures, and our recommended prevention measures (read).
| Chung, J. F. Fast tracking C010DS Zn: PARP1 agonist targeting cancer and M2-like macrophages. Translational Oncology Summit (24 Sep 2020)
This was an invited lecture at Translational Oncology Summit, hosted by Champions Oncology. This is the first disclosure event where we expressed our view on the resemblance between the macrophages of advanced cancers and the COVID-reprogrammed macrophages, predicted the future risks of poorer cancer prognosis, and proposed the dysfunctional macrophages as the therapeutic targets for treating the future aggressive cancers and post-COVID syndromes. (read).
PUBLICATIONS
| Chung, J. F., Lee, S.K. & Sood, A.K. Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. Oncotarget (2017)
This was the published work that first proposed the ageing physical features of micro blood vessels as a determinant factor toward the new concept of “effective immunity” governing cancer development and treatment. The term "effective immunity” captured the new idea that the real immunity effects must be defined as the product between individual immune cell activity, and its distribution through vascular system (read).
| Chung, J. F., Her, Z., Kong, W. M. & Chen, Q. Parthanatos-inducing zinc agent C010DS-Zn elicits anti-tumor immune responses involving T cells and macrophages in vivo. Pharmacovigilance and Drug Safety (2021).
This was the published work that disclosed and demonstrated the pharmacology and mechanism evidence for the parthanatos-inducing candidate drug agent C010DS-Zn, which included its in vivo normalization activity against the M2-like macrophages inside tumor (read).
| Chung, J. F. Future oncology concerns from post-COVID19 macrophage aberrations. EC Pharmacology and Toxicology (2021).
This was the published work that disclosed our projections of future “supercharged” cancers post-COVID infections due to COVID-reprogrammed macrophages (read).
| Chung, J. F. COVID19 Vaccine's Delta Paradox and Dangers of Further Viral Evolution. EC Pharmacology and Toxicology (2021).
Field evidence available at the time of Delta-wave was analyzed to assess vaccine effectiveness against SARS-CoV-2 variants, and the risks of mass vaccination accelerating the viral evolution. Recommendations for the future pandemic policies were also made (read).
| Chung, J. F. Long COVID, Non-COVID19 Excess Deaths, and Post-Pandemic Cardiovascular Disease Risks: Mechanistic Links and Intervention Opportunities. Medical Research Archives (2023)
This was the first publication that identified long COVID as a possible causal driver of the non-COVID19 excess deaths that are happening world-wide, with recommendations on its prevention and future management (read).
What we know about the mysterious pneumonia outbreak that is currently spreading around the world - December 2023